Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT07288177. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo. The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.
Study identification
- NCT ID
- NCT07288177
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 240 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 29, 2026
- Primary completion
- Nov 21, 2027
- Completion
- Nov 21, 2028
- Last update posted
- Aug 25, 2026
2026 – 2028
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Compassionate Cancer Care Center | Fountain Valley | California | 92708 | Recruiting |
| Kaiser Permanente San Diego Mission Road | San Diego | California | 92108 | Recruiting |
| Providence Medical Foundation (St. Joseph Heritage Healthcare) | Santa Rosa | California | 95403 | Recruiting |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | Recruiting |
| Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | Recruiting |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30322 | Recruiting |
| St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | Recruiting |
| Nebraska Hematology-Oncology | Lincoln | Nebraska | 68506 | Recruiting |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | Recruiting |
| ONE Onc: New York Oncology Hematology | Albany | New York | 12206 | Recruiting |
| Montefiore Medical Park | The Bronx | New York | 10461 | Recruiting |
| UNC Health - University of North Carolina | Chapel Hill | North Carolina | 27514 | Recruiting |
| Williamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | Recruiting |
| Providence Portland Medical Center | Portland | Oregon | 97213 | Recruiting |
| Providence Oncology & Hematology Care Clinic - Westside | West Haven-Sylvan | Oregon | 97225 | Recruiting |
| Tennessee Oncology - Nashville St. Thomas Midtown Clinic | Nashville | Tennessee | 37203 | Recruiting |
| Tennessee Oncology Nashville - SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | Recruiting |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07288177, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07288177 live on ClinicalTrials.gov.